Last reviewed · How we verify
Renal Disease with Edema — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zaroxolyn | METOLAZONE | I3 Pharms | Thiazide-like Diuretic [EPC] | Carbonic anhydrase 7 | 1973-01-01 | |
| Torasemide | Torasemide | Medical University of Warsaw | Solute carrier family 12 member 1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Renal Disease with Edema
- I3 Pharms · 1 drug in Renal Disease with Edema
- Medical University of Warsaw · 1 drug in Renal Disease with Edema
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Renal Disease with Edema:
- Renal Disease with Edema treatment updates — RSS
- Renal Disease with Edema treatment updates — Atom
- Renal Disease with Edema treatment updates — JSON
Cite this brief
Drug Landscape (2026). Renal Disease with Edema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/renal-disease-with-edema. Accessed 2026-06-11.
Related
- Renal Disease with Edema full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing